Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejca.2023.113263 | DOI Listing |
J Pain Res
January 2025
Department of Anesthesiology, Women's Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital, Nanjing, 210004, People's Republic of China.
Stat Med
February 2025
Institute of Medical Biometry, Ruprecht-Karls University Heidelberg, Heidelberg, Germany.
Biomark Res
January 2025
Incyte Corporation, Wilmington, DE, USA.
Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adults ineligible for autologous stem cell transplantation. This retrospective analysis examined characteristics and outcomes of adults with R/R DLBCL who received tafasitamab preceding CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in a real-world setting.
View Article and Find Full Text PDFHand (N Y)
January 2025
Department of Surgery, Division of Plastic Surgery, McMaster University, Hamilton, ON, Canada.
Am J Obstet Gynecol MFM
January 2025
Department of Medicine, University Potiguar, Natal, Brazil.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!